Page last updated: 2024-12-08

monoisoamyl-2,3-dimercaptosuccinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

monoisoamyl-2,3-dimercaptosuccinate: monoisoamyl ester of meso-2,3-dimercaptosuccinic acid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID164448
MeSH IDM0242675

Synonyms (14)

Synonym
monoisoamyl meso-2,3-dimercaptosuccinate
monoisoamyl-2,3-dimercaptosuccinate
butanedioic acid, 2,3-dimercapto-, mono(3-methylbutyl) ester, (r*,s*)-
mono(3-methylbutyl) 2,3-dimercaptobutanedioate (r*,s*)-
monoisoamyl 2,3-dimercaptosuccinic acid
142609-62-9
(2s,3r)-4-(3-methylbutoxy)-4-oxo-2,3-bis(sulfanyl)butanoic acid
unii-9o8b0vbe22
9o8b0vbe22 ,
mono-isoamyl2,3-dimercaptosuccinate
isoamyl 2,3-dimercaptosuccinate
butanedioic acid, 2,3-dimercapto-, 1-(3-methylbutyl) ester, (2r,3s)-rel-
rel-(2s,3r)-4-(isopentyloxy)-2,3-dimercapto-4-oxobutanoic acid
AT37305

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" IR spectroscopy further suggested that MiADMSA bind to arsenic to form adduct, which prevents arsenic from exerting its toxic effect in both models."( Monoisoamyl dimercaptosuccinic acid abrogates arsenic-induced developmental toxicity in human embryonic stem cell-derived embryoid bodies: comparison with in vivo studies.
Flora, SJ; Mehta, A, 2009
)
0.35
"Exposure to toxic metals remains a widespread occupational and environmental problem in world."( Nanoencapsulation of DMSA monoester for better therapeutic efficacy of the chelating agent against arsenic toxicity.
Babbar, AK; Flora, SJ; Kaushik, MP; Kushwaha, P; Lomash, V; Mathur, R; Mishra, AK; Pathak, U; Samim, M; Yadav, A, 2014
)
0.4
"Chelation therapy is considered as a safe and effective strategy to combat metal poisoning."( Comparative efficacy of Nano and Bulk Monoisoamyl DMSA against arsenic-induced neurotoxicity in rats.
Flora, SJS; Kumar, P; Naqvi, S, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" We also carried out a pharmacokinetic analysis of this drug to support arsenic chelation."( Monoisoamyl 2, 3-dimercaptosuccinic acid (MiADMSA) demonstrates higher efficacy by oral route in reversing arsenic toxicity: a pharmacokinetic approach.
Bhadauria, S; Flora, SJ; Pachauri, V; Yadav, A, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (18.75)18.2507
2000's19 (39.58)29.6817
2010's15 (31.25)24.3611
2020's5 (10.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.71 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other51 (96.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]